Sign inJoin waitlistJoin the waitlist

Mohammed Almubarak

Associate Professor, Department of Medical Oncology · West Virginia University School of Medicine

Credentials: · · · ·

History

West Virginia University School of Medicine
Present

Hematology and Medical Oncology
West Virginia University School of Medicine
2006–2009
Internal Medicine
West Virginia University School of Medicine
2003–2006
George Washington Univ Sch of Med
1999–2003

Research

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
European Journal of Endocrinology · 2022 · 139 citations
Guideline-concordant lung cancer care and associated health outcomes among elderly patients in the United States
Journal of Geriatric Oncology · 2015 · Last of 6 authors · 63 citations
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial
Clinical Cancer Research · 2022 · 43 citations

Patrick Ma
3 papers
AC
Alexander Chi
2 papers
AD
Alexander Drilon
2 papers
David Clump
2 papers
David Hong
2 papers
Gary Marano
2 papers
Gregory Daniels
2 papers
Jame Abraham
2 papers
Jessica Bauman
2 papers
John Knoth
2 papers · 2 as a resident
JR
John Rogers
2 papers
Malcolm Mattes
2 papers

Clinical trials

1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX
Principal investigator · Terminated · Phase 2
West Virginia University
2012–2014
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027